Hormonal
Dietary fiber fermentation by gut microbiota produces short-chain fatty acids (SCFAs) which stimulate the secretion of gut peptides (GLP-1, PYY) via GPR41/GPR43 receptors, thereby improving glucose regulation and reducing energy intake.
To leverage your gut microbiome for better blood sugar control and appetite regulation, consume complex carbohydrates (dietary fibers) that resist digestion in the small intestine. These fibers reach the colon where bacteria ferment them into short-chain fatty acids (SCFAs). These SCFAs activate specific receptors (GPR41/43) on gut cells, triggering the release of hormones like GLP-1 and PYY that improve glucose handling and reduce hunger. Focus on sources like resistant starches and arabinoxylans.
modulating the gut microbiota using prebiotics led to a higher endogenous production (ie, mRNA and peptides) and portal vein secretion of several gut peptides produced by the L- cells such as GLP- 1, GLP- 2 and peptide YY (PYY)... SCFAs stimulate the secretion of gut peptides by acting on specific G- protein- coupled receptors... GPR43 (or free fatty acid receptor 2 (FFAR2)) and GPR41 (or FFAR3)
Why this rating
The paper cites multiple human and mouse studies establishing the link, though it is a review of mechanisms rather than a single clinical trial.
Source
Gut microbiome and health: mechanistic insights
Willem M. de Vos et al. · Gut · 2022
DOI 10.1136/gutjnl-2021-326789
More from this paper
- Butyrate maintains anaerobic conditions in the colon by activating PPARγ and repressing inducible nitric oxide synthase (iNOS), which prevents the proliferation of pathogenic facultative anaerobes like Enterobacteriaceae.Good
- Metabolic endotoxaemia, characterized by elevated circulating lipopolysaccharides (LPS) due to increased gut permeability, drives low-grade chronic inflammation associated with type 2 diabetes, NAFLD, and obesity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →